Evidence map›Paper›PMID 36010896›Full record

ArticleCancers2022

Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate.

Maria A Papadaki, Anastasia Mala, Aikaterini C Merodoulaki, Maria Vassilakopoulou, Dimitrios Mavroudis, Sofia Agelaki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Maria A PapadakiLaboratory of Translational Oncology, School of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0002-6363-7258
Anastasia MalaLaboratory of Translational Oncology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Aikaterini C MerodoulakiLaboratory of Translational Oncology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Maria VassilakopoulouLaboratory of Translational Oncology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Dimitrios MavroudisLaboratory of Translational Oncology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Sofia AgelakiLaboratory of Translational Oncology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
University of Crete · GR

Funding

Anticancer Research Support Association (ARSA), Heraklion, Greece Research_Funding_2020Hellenic Society of Medical Oncology (HESMO) Research_Funding_2018
6 · The paper itself

Abstract

We herein aimed to assess the effect of eribulin mesylate on the cancer stem cell (CSC)/EMT-like phenotype of CTCs, and to investigate the prognostic role of CTC detection and monitoring for eribulin-treated BC patients. Peripheral blood was obtained at baseline (

Indexed as

biomarkersbreast cancerbreast cancer (BC)cancer stem cells (CSCs)circulating tumor cells (CTCs)CTC monitoringepithelial-to-mesenchymal transition (EMT)eribulin mesylateliquid biopsyresistance

Identifiers

PMID36010896
PMCPMC9405936
OpenAlexW4291367004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.